Abbott Laboratories (NYSE:ABT) Holdings Decreased by Capital Advisors Ltd. LLC

Capital Advisors Ltd. LLC lessened its stake in Abbott Laboratories (NYSE:ABTGet Rating) by 39.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,689 shares of the healthcare product maker’s stock after selling 1,090 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in Abbott Laboratories were worth $200,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. TRH Financial LLC boosted its stake in Abbott Laboratories by 23.2% during the 1st quarter. TRH Financial LLC now owns 73,590 shares of the healthcare product maker’s stock valued at $8,710,000 after purchasing an additional 13,864 shares in the last quarter. Samalin Investment Counsel LLC lifted its holdings in shares of Abbott Laboratories by 5.5% in the fourth quarter. Samalin Investment Counsel LLC now owns 3,311 shares of the healthcare product maker’s stock valued at $466,000 after buying an additional 172 shares during the period. Kavar Capital Partners Group LLC boosted its stake in Abbott Laboratories by 4.9% during the first quarter. Kavar Capital Partners Group LLC now owns 46,450 shares of the healthcare product maker’s stock valued at $5,498,000 after buying an additional 2,162 shares in the last quarter. Foundations Investment Advisors LLC grew its holdings in Abbott Laboratories by 5.2% during the first quarter. Foundations Investment Advisors LLC now owns 8,735 shares of the healthcare product maker’s stock worth $1,028,000 after acquiring an additional 433 shares during the period. Finally, Clarity Financial LLC lifted its holdings in Abbott Laboratories by 1.9% in the 1st quarter. Clarity Financial LLC now owns 36,090 shares of the healthcare product maker’s stock valued at $4,272,000 after acquiring an additional 680 shares during the last quarter. Institutional investors and hedge funds own 73.46% of the company’s stock.

Abbott Laboratories Stock Performance

ABT stock opened at $109.25 on Friday. The stock has a market cap of $191.32 billion, a P/E ratio of 22.81, a P/E/G ratio of 4.06 and a beta of 0.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 2.01. The firm has a 50 day simple moving average of $109.35 and a 200 day simple moving average of $115.75. Abbott Laboratories has a 52 week low of $101.24 and a 52 week high of $142.60.

Abbott Laboratories (NYSE:ABTGet Rating) last posted its quarterly earnings results on Wednesday, July 20th. The healthcare product maker reported $1.43 EPS for the quarter, beating the consensus estimate of $1.09 by $0.34. Abbott Laboratories had a net margin of 18.78% and a return on equity of 29.38%. The business had revenue of $11.26 billion for the quarter, compared to analysts’ expectations of $10.37 billion. During the same period in the previous year, the company posted $1.17 EPS. Abbott Laboratories’s revenue was up 10.1% on a year-over-year basis. Research analysts anticipate that Abbott Laboratories will post 5 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Thursday, July 14th. This represents a $1.88 annualized dividend and a dividend yield of 1.72%. Abbott Laboratories’s dividend payout ratio is 39.25%.

Analyst Ratings Changes

Several brokerages have recently issued reports on ABT. Cowen lowered their price objective on shares of Abbott Laboratories from $150.00 to $130.00 in a research note on Wednesday, July 13th. Wells Fargo & Company dropped their price target on Abbott Laboratories from $155.00 to $150.00 and set an “overweight” rating on the stock in a report on Friday, April 8th. Citigroup reduced their price objective on Abbott Laboratories from $125.00 to $123.00 and set a “buy” rating for the company in a research note on Thursday, July 21st. Raymond James cut their target price on Abbott Laboratories from $143.00 to $135.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. Finally, Evercore ISI dropped their price target on Abbott Laboratories to $112.00 in a research note on Friday, July 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $132.46.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $109.14, for a total value of $5,457,000.00. Following the completion of the sale, the director now directly owns 6,923,500 shares of the company’s stock, valued at $755,630,790. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Fernando Mateus sold 2,457 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $109.05, for a total value of $267,935.85. Following the completion of the sale, the senior vice president now directly owns 14,503 shares in the company, valued at approximately $1,581,552.15. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel J. Starks sold 50,000 shares of the stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $109.14, for a total value of $5,457,000.00. Following the transaction, the director now owns 6,923,500 shares in the company, valued at approximately $755,630,790. The disclosure for this sale can be found here. 0.52% of the stock is currently owned by company insiders.

Abbott Laboratories Profile

(Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

See Also

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTGet Rating).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.